Background. Alanine aminotransferase (ALT) flares occur frequently during peginterferon (PEG-IFN) therapy. We related occurrence of flares to presence of precore (PC) and/or basal core promoter (BCP) mutants and studied kinetics of hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) levels during flares.Methods. Fifty of 214 (23%) patients treated with PEG-IFN ± lamivudine for 52 weeks experienced flares. Flares were host-induced (ALT elevation followed by HBV DNA decline, n = 19), virus-induced (HBV DNA increase with subsequent ALT elevation, n = 17) or indeterminate (n = 14
Treatment options for patients with chronic hepatitis B (CHB) and hepatitis B e antigen (HBeAg)-nega...
Background & Aims: No information is available about the frequency or factors that predict spont...
BACKGROUND & AIMS: The role of quantitative hepatitis B surface antigen (HBsAg) after hepatitis B e-...
Background. Alanine aminotransferase (ALT) flares occur frequently during peginterferon (PEG-IFN) th...
textabstractBackground. Alanine aminotransferase (ALT) flares occur frequently during peginterferon ...
Background: Alanine aminotransferase (ALT) is one of the main indicators for inflammatory activity i...
Flares are a well known phenomenon during antiviral treatment for chronic hepatitis B. Little is kno...
Background and aims: Flares are a well known phenomenon during antiviral treatment for chronic hepat...
BACKGROUND: Alanine aminotransferase (ALT) flares during NA therapy are uncommon but occur. Evaluati...
Background We aimed to determine the frequency of alanine aminotransferase (ALT) elevation during in...
SummaryHepatitis B flare, defined as an event with abrupt rise of alanine aminotransferase (ALT) lev...
WOS: 000317709400013PubMed ID: 23274785Hepatitis B e antigen (HBeAg) levels may predict response to ...
Background: Pegylated interferon (PEG-IFN)-alpha-2a improves the hepatitis B e antigen (HBeAg) seroc...
Peginterferon alfa-2a results in a sustained response (SR) in a minority of patients with hepathis B...
Precore (PC) (G1896A) and basal core promoter (BCP) (A1762T/G1764A) mutations of the hepatitis B vir...
Treatment options for patients with chronic hepatitis B (CHB) and hepatitis B e antigen (HBeAg)-nega...
Background & Aims: No information is available about the frequency or factors that predict spont...
BACKGROUND & AIMS: The role of quantitative hepatitis B surface antigen (HBsAg) after hepatitis B e-...
Background. Alanine aminotransferase (ALT) flares occur frequently during peginterferon (PEG-IFN) th...
textabstractBackground. Alanine aminotransferase (ALT) flares occur frequently during peginterferon ...
Background: Alanine aminotransferase (ALT) is one of the main indicators for inflammatory activity i...
Flares are a well known phenomenon during antiviral treatment for chronic hepatitis B. Little is kno...
Background and aims: Flares are a well known phenomenon during antiviral treatment for chronic hepat...
BACKGROUND: Alanine aminotransferase (ALT) flares during NA therapy are uncommon but occur. Evaluati...
Background We aimed to determine the frequency of alanine aminotransferase (ALT) elevation during in...
SummaryHepatitis B flare, defined as an event with abrupt rise of alanine aminotransferase (ALT) lev...
WOS: 000317709400013PubMed ID: 23274785Hepatitis B e antigen (HBeAg) levels may predict response to ...
Background: Pegylated interferon (PEG-IFN)-alpha-2a improves the hepatitis B e antigen (HBeAg) seroc...
Peginterferon alfa-2a results in a sustained response (SR) in a minority of patients with hepathis B...
Precore (PC) (G1896A) and basal core promoter (BCP) (A1762T/G1764A) mutations of the hepatitis B vir...
Treatment options for patients with chronic hepatitis B (CHB) and hepatitis B e antigen (HBeAg)-nega...
Background & Aims: No information is available about the frequency or factors that predict spont...
BACKGROUND & AIMS: The role of quantitative hepatitis B surface antigen (HBsAg) after hepatitis B e-...